Entrada Therapeutics Inc (TRDA)

$5.28 -0.01 (-0.19%)
Market Cap 201.22M
Revenue (ttm) 210.78M
Net Income (ttm) 65.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 31.14%
Debt to Equity Ratio 0.00
Volume 346,400
Avg Vol 213,034
Day's Range N/A - N/A
Shares Out 38.04M
Stochastic %K 12%
Beta -0.13
Analysts Strong Sell
Price Target $18.50

Company Profile

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 520 9158
Address:
One Design Center Place, Suite 17- 500, Boston, United States
prismmarketview
prismmarketview Sep. 5 at 2:51 PM
$TRDA #EntradaTherapeutics is investing in life beyond the lab. The company has awarded $100,000 in “Dream Grants” to patient groups affected by Duchenne muscular dystrophy, offering critical support for advocacy, quality of life, and community initiatives. By strengthening the human element of the treatment journey, Entrada reinforces its deep commitment to those it aims to serve. https://prismmarketview.com/entrada-awards-100k-in-dreams-grants-to-support-duchenne-patient-communities/
0 · Reply
VinWeezel
VinWeezel Sep. 3 at 2:11 PM
$TRDA started hiring…
0 · Reply
mhaven2020
mhaven2020 Aug. 28 at 6:49 PM
$THAR had some early this week. Here are the alerts up to this morning. Follow and sign up for trade alerts on our website if you want to be days early also. $TRDA $ACET $SNAL
0 · Reply
mhaven2020
mhaven2020 Aug. 24 at 4:54 PM
$CGTX this machine learning part tells me which zones won most consistently. $TRDA $SSP
0 · Reply
mhaven2020
mhaven2020 Aug. 24 at 4:09 PM
$MERC $CGTX $TRDA working on the backtest for the alerted tickers to see which are most likely to hold any gains...
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:44 PM
$TRDA here are the machine results for that same set of data. Showing adx zone -1 had 4 times . I like the rsi zone 1 at 10 times won ADX RANGE 0.79 to 2.36 won more than other ones. RSI RANGE 1 at 42.72 to 50.9. That's how that part comes together. It really is a strong system. Come join the parties on time instead of being late and missing the move. $CLNE $AIOT $ASPI. If you want days notice before a stock moves, sign up on our website. Link in bio.
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:36 PM
$TRDA $MERC and whoever else. This is the backtesting results for some earlier this week.
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:34 PM
$TRDA there were 55 shared market movers between August and July. Here are the ones triggering the most (the hot list). I also built a machine learning module where it tells me what indicators values should be for the highest probability wins. I'll be digging into some of these also. Do your own research and make sure that any stock fits within your risk tolerance. $ANTE $ZYXI $AREC $OPEN
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:23 PM
$TRDA Here are the 11 that were in the week prior and this past week . I'll be checking these out over the weekend. $MSOX $ANTE $OPEN.
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:18 PM
$TRDA My trade commando scanner takes snapshots and saves them as pdfs. I scan the markwt movers and have an aechive of 3 months of market movers, plus daily scans. My favorite thing to do is compare market movers week to week and then find the best ones. Those sometimes are the alerts, sometimes not. $CLGN $IMRX $CATO
0 · Reply
Latest News on TRDA
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Sep 5, 2025, 7:00 AM EDT - 3 days ago

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 4:30 PM EDT - 6 days ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 4 weeks ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 3, 2025, 7:00 AM EDT - 3 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025, 7:00 AM EDT - 3 months ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 4 months ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Mar 24, 2025, 7:00 AM EDT - 6 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 6 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 24, 2025, 7:00 AM EST - 7 months ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 19, 2025, 11:31 AM EST - 7 months ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Feb 3, 2025, 7:00 AM EST - 7 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Jan 30, 2025, 4:05 PM EST - 7 months ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:00 AM EST - 9 months ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Oct 9, 2024, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 17, 2024, 8:30 AM EDT - 1 year ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 7:15 AM EDT - 1 year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 16, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Entrada Therapeutics Reports First Quarter 2024 Financial Results

May 7, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics to Present at Upcoming Investor Conferences

Feb 7, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Nov 22, 2023, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Entrada Therapeutics: Early Stage But Interesting

Aug 3, 2023, 6:39 PM EDT - 2 years ago

Entrada Therapeutics: Early Stage But Interesting

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Entrada Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Apr 4, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 29, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Dec 19, 2022, 4:30 PM EST - 2 years ago

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 8:24 AM EST - 2 years ago

Entrada Therapeutics shares jump on collaboration with Vertex

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Dec 8, 2022, 7:00 AM EST - 2 years ago

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

VRTX

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Nov 7, 2022, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

Jul 19, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Jul 6, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Jun 1, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Entrada Therapeutics Reports First Quarter 2022 Financial Results

May 12, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2022 Financial Results

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

May 11, 2022, 9:30 AM EDT - 3 years ago

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

Apr 18, 2022, 9:48 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

ATER NEGG BEEM

prismmarketview
prismmarketview Sep. 5 at 2:51 PM
$TRDA #EntradaTherapeutics is investing in life beyond the lab. The company has awarded $100,000 in “Dream Grants” to patient groups affected by Duchenne muscular dystrophy, offering critical support for advocacy, quality of life, and community initiatives. By strengthening the human element of the treatment journey, Entrada reinforces its deep commitment to those it aims to serve. https://prismmarketview.com/entrada-awards-100k-in-dreams-grants-to-support-duchenne-patient-communities/
0 · Reply
VinWeezel
VinWeezel Sep. 3 at 2:11 PM
$TRDA started hiring…
0 · Reply
mhaven2020
mhaven2020 Aug. 28 at 6:49 PM
$THAR had some early this week. Here are the alerts up to this morning. Follow and sign up for trade alerts on our website if you want to be days early also. $TRDA $ACET $SNAL
0 · Reply
mhaven2020
mhaven2020 Aug. 24 at 4:54 PM
$CGTX this machine learning part tells me which zones won most consistently. $TRDA $SSP
0 · Reply
mhaven2020
mhaven2020 Aug. 24 at 4:09 PM
$MERC $CGTX $TRDA working on the backtest for the alerted tickers to see which are most likely to hold any gains...
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:44 PM
$TRDA here are the machine results for that same set of data. Showing adx zone -1 had 4 times . I like the rsi zone 1 at 10 times won ADX RANGE 0.79 to 2.36 won more than other ones. RSI RANGE 1 at 42.72 to 50.9. That's how that part comes together. It really is a strong system. Come join the parties on time instead of being late and missing the move. $CLNE $AIOT $ASPI. If you want days notice before a stock moves, sign up on our website. Link in bio.
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:36 PM
$TRDA $MERC and whoever else. This is the backtesting results for some earlier this week.
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:34 PM
$TRDA there were 55 shared market movers between August and July. Here are the ones triggering the most (the hot list). I also built a machine learning module where it tells me what indicators values should be for the highest probability wins. I'll be digging into some of these also. Do your own research and make sure that any stock fits within your risk tolerance. $ANTE $ZYXI $AREC $OPEN
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:23 PM
$TRDA Here are the 11 that were in the week prior and this past week . I'll be checking these out over the weekend. $MSOX $ANTE $OPEN.
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 11:18 PM
$TRDA My trade commando scanner takes snapshots and saves them as pdfs. I scan the markwt movers and have an aechive of 3 months of market movers, plus daily scans. My favorite thing to do is compare market movers week to week and then find the best ones. Those sometimes are the alerts, sometimes not. $CLGN $IMRX $CATO
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 10:26 PM
$CGTX since all of these have played out already, i can share them. People pay me to send alerts daily , so i can't be sharing all the goodies real time. Purple is losses - 5 out of 48. Lol, almost 90%win rate. Overall batting average climbed to 69% ! $MERC, $TRDA and $MFH for a few days into next week. Want these alerts? Link in bio!
0 · Reply
Tradr1205
Tradr1205 Aug. 18 at 7:01 PM
$TRDA Trending up!! Let's get back over $6.50/$7 this week
1 · Reply
maizeblue22
maizeblue22 Aug. 13 at 6:17 PM
$TRDA is developing a platform technology that has high impact potential. A lot of people in the biotech ecosystem are excited about it and have been for 5y. Co is also trading under cash. Why is this down so much?
1 · Reply
Tradr1205
Tradr1205 Aug. 6 at 4:42 PM
$TRDA I bought another large chunck this morning. This stock is crazy undervalued! Too much upside to pass up!
1 · Reply
gilheydari
gilheydari Aug. 6 at 3:12 PM
$TRDA I guess manipulated badly, looks at volume and percentage drop!
0 · Reply
VinWeezel
VinWeezel Aug. 6 at 3:09 PM
$TRDA now a market cap of 194 million. 350 million in cash. Thoughts?
1 · Reply
d_risk
d_risk Aug. 6 at 1:30 PM
$TRDA - Entrada Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors TRDA’s 2025 10-Q risk update highlights extended cash runway to mid-2025, heavy reliance on lead candidate ENTR-601-44, expanded regulatory, IP, and commercialization risks, intensified talent retention challenges amid workforce cuts, increased legal and cybersecurity exposures, and new risks from strategic transactions, tax law changes, and public company compliance burdens. #Biotechnology #Cybersecurity #TalentRetention #RegulatoryRisk #DrugDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/TRDA/10-Q/2025-08-06
1 · Reply
VinWeezel
VinWeezel Aug. 6 at 12:17 PM
$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-reports-second-quarter-2025-financial-nyq4651jnxvr.html
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 26 at 1:49 PM
$TRDA I’ve started a position at these levels. Clinical stage biotech with minimal spend, partnership and licensing revenues from a strong rare disease biotech player trading below cash. Another potential headwind that seems to have missed entrada so far is that they’re delivering a gene therapy without the potential/perceived harm of AAV viral vectors (eg $SRPT). Will buy/build more, if it dips further. My only critique is that they don’t give guidance on future trial readouts in their corporate pdf so not sure when the catalyst events will take place.
0 · Reply
Tradr1205
Tradr1205 Jul. 15 at 4:45 PM
$TRDA Bought some more. This is over-blown. Reversal forthcoming
2 · Reply
VinWeezel
VinWeezel Jul. 15 at 3:59 PM
$TRDA prolly more 5am ventures selling-Market selling tiny bits into 0 volume. Downward pressure. Not ideal days here.
2 · Reply
Tradr1205
Tradr1205 Jul. 11 at 6:01 AM
$TRDA Bought a nice chunck before the market closed. I think we're trading back above $7 in the am
0 · Reply